Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma

Heather A. Personett, Erin F. Barreto, Kristen B. McCullough, Ross Dierkhising, Nelson Leung, Thomas M. Habermann

Research output: Contribution to journalArticlepeer-review


Early administration of rasburicase to enhance uric acid (UA) elimination has been adopted without robust evidence in support of its impact on clinical outcomes in tumor lysis syndrome (TLS), specifically, the prevention of acute kidney injury (AKI). This was a retrospective cohort study of adult lymphoma patients at intermediate or high risk for TLS. Excluded patients had AKI or were on dialysis at hospital admission. The incidence of new AKI in the setting of TLS was described along with predictors of its development, including early rasburicase use. In 383 included patients, the incidence of new-onset AKI during hospitalization was 6%. Predictors included age, history of renal or cardiovascular disease, and UA >8 mg/dL. Rasburicase use did not significantly impact the risk of developing AKI (HR 2.3; p =.11). The UA level at the time of administration did not modify the effect of rasburicase on prevention of AKI (p =.36 for the interaction term).

Original languageEnglish (US)
Pages (from-to)2271-2277
Number of pages7
JournalLeukemia and Lymphoma
Issue number9
StatePublished - Jul 29 2019


  • Lymphoma and Hodgkin disease
  • acute kidney injury
  • lymphoid leukemia
  • pharmacotherapeutics
  • rasburicase
  • tumor lysis syndrome

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma'. Together they form a unique fingerprint.

Cite this